ChemPartner PharmaTech Co.,Ltd. (SHE:300149)
China · Delayed Price · Currency is CNY 10.81
-0.37 (-3.31%)
At close: Apr 21, 2026
ChemPartner PharmaTech Revenue
ChemPartner PharmaTech had revenue of 283.05M CNY in the quarter ending September 30, 2025, with 11.72% growth. This brings the company's revenue in the last twelve months to 1.07B, up 5.72% year-over-year. In the year 2024, ChemPartner PharmaTech had annual revenue of 970.20M, down -14.77%.
Revenue (ttm)
1.07B
Revenue Growth
+5.72%
P/S Ratio
5.04
Revenue / Employee
589.04K
Employees
1,814
Market Cap
5.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 970.20M | -168.16M | -14.77% |
| Dec 31, 2023 | 1.14B | -188.22M | -14.19% |
| Jan 1, 2023 | 1.33B | -364.09M | -21.54% |
| Jan 1, 2022 | 1.69B | 209.09M | 14.11% |
| Dec 31, 2020 | 1.48B | 153.77M | 11.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.26B |
| Wuhan Hvsen Biotechnology | 1.68B |
| Kexing Biopharm | 1.54B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Beijing Konruns Pharmaceutical | 871.31M |
| PharmaResources (Shanghai) | 667.47M |
| Lifecome Biochemistry | 502.95M |
| Assure Tech (Hangzhou) | 453.58M |